Competing interests
C.B.F. declares no competing non-financial interests but the following competing financial interests. C.B.F. is co-inventor on patents claiming priority to WO/2015/103167, single-vial vaccine formulations, and WO/2013/119856, improved adjuvant formulations comprising TLR4 agonists and methods of using the same. The remaining authors declare no competing interests.